Stock comparison
Exelixis
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EXEL
Exelixis
Market cap
$12.61B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Exelixis EXEL
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EXEL | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 65C | GMAB |
| Benjamin Graham | 74B | 64C | EXEL |
| Philip Fisher | 74B | 48D | EXEL |
| Peter Lynch | 58C | 25F | EXEL |
| Joel Greenblatt | 60C | 76B | GMAB |
| Charlie Munger | 71B | 68C | EXEL |
| Terry Smith | 80A | 71C | EXEL |
Side-by-side metrics
| Metric | EXEL | GMAB |
|---|---|---|
| Market cap | $12.61B | $16.5B |
| P/E (TTM) | 15.3x | 6.2x |
| EV/EBIT | 14.2x | 12.0x |
| ROIC (TTM) | 35.01% | 43.78% |
| Gross margin | 96.44% | 93.88% |
| Net margin | 35.08% | 18.23% |
| Revenue CAGR 5y | 12.76% | -18.45% |
| EPS CAGR 5y | 40.93% | -23.48% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EXEL leads on
- Revenue CAGR 5y12.76%vs -18.45%+169%
- EPS CAGR 5y40.93%vs -23.48%+157%
- Net margin35.08%vs 18.23%+48%
GMAB leads on
- P/E (TTM)6.2xvs 15.3x+60%
- Market cap$16.5Bvs $12.61B+24%
- ROIC (TTM)43.78%vs 35.01%+20%
- Debt / Equity0.1xvs 0.1x+16%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.